Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Genedata Biologics on the Rise at Pharmas and Biotechs

Published: Wednesday, April 25, 2012
Last Updated: Wednesday, April 25, 2012
Bookmark and Share
Top 30 pharmas and leading biotech firms building IT infrastructure for biopharmaceutical R&D on Genedata Biologics platform

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that within its first year on the market, Genedata Biologics has been adopted by several leading pharmaceutical and biotech companies as their biotherapeutics R&D data management platform. Genedata Biologics' rapid adoption is attributed to its unique built-in domain knowledge that addresses key requirements of the biopharmaceutical discovery and development process, which is fundamentally different from the classic small-molecule-based drug discovery process. Genedata cites that more than 25% of the leading pharmaceutical companies have already licensed Genedata Biologics, a first-in-class, end-to-end solution for biologics R&D. Covering the full antibody screening, protein engineering, and biologics production process.

"The pharmaceutical industry is going through a seismic shift from small-molecule, chemical drug discovery to large-molecule, biological drug discovery," said Dr. Othmar Pfannes, CEO of Genedata. "This industry shift is analogous to the differences in building a single-family home to building a 1,000-foot office building," continued Dr. Pfannes. "The processes and technologies used for building a small home don't translate to large-scale construction projects. Similarly, software that supported chemical-based drug discovery cannot be repurposed to support novel and complex biologics  processes. Genedata Biologics is a first-in-class platform dedicated to support the full biologics R&D process." 

Tailored for Large-molecule R&D Requirements
While biologics R&D has matured in recent years, the underlying discovery and development process differs substantially from small-molecule R&D, posing unique challenges for pharma and biotech companies. Unlike classic small-molecule drugs, biologics are very large molecules with high molecular complexity. For example, a therapeutic antibody contains more than 25,000 atoms while a small molecule such as aspirin consists of only 21 atoms. Large biological molecules tend to be sensitive to production-process changes and can only be produced by living systems (e.g. mammalian cell cultures), which requires extremely complex and costly biotechnological processes. Specialized groups, focused on specific tasks and technologies, collaborate along the R&D workflow, which results in multiple sample and data handovers (e.g. screening, engineering, cloning, cell line development, expression, purification, and analytics). Scientists must be able to access all relevant sequence or assay information as well as analytics produced by groups working upstream. Genedata Biologics enables easy sharing of such information and helps eliminate data handling errors, tasks which can no longer be handled manually or by sharing spreadsheets.

"We see our customers - specifically large pharmas and biotechs - building up new capabilities or extending their current biopharmaceutical R&D processes. Consequently, they need a way to manage their newly established processes with the ability to annotate, track, and handle all resulting biologics molecules and samples," noted Dr. Pfannes. "Managing all this valuable data in one dedicated and integrated system is important from an IP perspective. Additionally, it streamlines the daily logistics processes in today's expansive biologics R&D groups, often comprised of hundreds of scientists and engineers, plus external partners and CROs."

Genedata Biologics provides comprehensive functionality for antibody screening, protein engineering, and biologics production. The platform integrates data management capabilities for managing biologics samples, molecules, assay and analytic data, by supporting:

- High-throughput processes for fully automated workflows via direct integration with lab automation and robotics, and tools for processing vast amounts of screening and process data. 
- Standardized lab processes for more efficient, faster and less manual data handling and processing (e.g. in-silico cloning enabling large-scale cloning campaigns, eliminating cut-and-paste errors in manual cloning). 
- Division-of-labor processes with centralized biologics registration and integrated workflow-support tools, which advance collaborative work among specialized biologics R&D groups. Every synthesized biologics drug candidate is accessible, editable, and transferrable among scientists and sites.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
Thursday, June 12, 2014
Genedata Showcases Integrated Analysis & Image Management Solution for Phenotypic Screening
Regardless of instrument or application, Genedata Screener® for High Content Screening enables time-efficient workflow for analysis of high-content experiments
Friday, February 21, 2014
Genedata Announces New Data Analysis Platform for Next-Gen Oncology Drug Discovery
AstraZeneca and Genedata detail a data analysis platform for compound combination experiments in oncology and other therapeutic areas
Monday, February 03, 2014
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research
Leading clinical-research institute of the Robert Bosch Stiftung uses Genedata Expressionist for managing, processing, and interpreting clinical NGS data
Monday, January 27, 2014
Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
Genedata Selector platform to manage, analyze, and integrate complex microbial genomes and strains will be showcased in 5th Annual NGS Conference Poster Session
Saturday, November 23, 2013
Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
Genedata Biologics will be implemented at multiple Sanofi R&D sites and departments to improve biologics discovery throughput and process efficiency.
Sunday, November 10, 2013
Evonik and Genedata broaden their collaboration with the Genedata Selector biotechnology data management platform
Genomic strain data management solution supports Evonik growth in biotechnology
Sunday, September 22, 2013
AB SCIEX, Genedata and LECO Announce Partnership
New collaborative software system will enable metabolomics researchers to comprehensively process and analyze experimental data across different GC/MS and LC/MS platforms.
Tuesday, July 02, 2013
Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Genedata collaborates with leading European institutions on the development of blood tests for early detection of major female cancers based on epigenetic markers
Saturday, April 06, 2013
Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
Genedata Expressionist will be demonstrated as a platform for automating and standardizing protein characterization that helps eliminate data analysis bottlenecks
Wednesday, March 13, 2013
Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
Global leader in drug discovery advances targeted proteomics and metabolomics with extended use of Genedata Expressionist®
Sunday, February 10, 2013
Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
More than half of the top 25 pharmaceutical companies now use Genedata Screener® to support plate-based screening, including High Content, Label-free, and Ion Channel Screening
Sunday, January 20, 2013
Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
carcinoGENOMICS and other EU-funded research consortia help Genedata advance software platform
Friday, December 28, 2012
Genedata Biologics for Streamlined Protein Engineering at PEGS Europe
UCB Pharma and Genedata will showcase data management and workflow system that captures production and characterization data for biotherapeutics and reagents
Sunday, November 11, 2012
UCB Pharma Advances Next-Generation Antibody Discovery with Genedata Biologics
Leader in protein therapeutics development extends use of Genedata Biologics for next-generation antibody-based therapeutics R&D
Thursday, September 20, 2012
Scientific News
Protecting Privacy in Genomic Databases
System helps ensure databases used in medical research will not leak patients’ personal information.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Pittcon 2016: Accelerating Innovation And Enhancing Productivity With Technology
Collaboration and externalization of data highlight evolving lab operations.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Researchers Construct Atomic Model of an Immature Retrovirus
Using molecular modeling and large-scale molecular dynamic simulation, Beckman researchers have constructed an atomic model of an immature retrovirus.
New Mathematics Advances the Frontier of Macromolecular Imaging
Berkeley Lab’s M-TIP solves the reconstruction problem for fluctuation X-ray scattering.
Exploring Living cells
JPK reports the exploration of living cells using nanoscale and single molecule techniques through the application of scanning probe microscopy.
The Perfect Partnership: Research & Industry; Software & Instrumentation. It really starts to come together at ASMS 2015
Collaboration and knowledge-sharing were evident everywhere: on the bus, in the hallways and in the bars. This article aims to capture this theme and share with you some of the fruits of this coming together of science and industry.
Designing New Pain Relief Drugs
Researchers have identified the molecular interactions that allow capsaicin to activate the body’s primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos